Acorda Therapeutics, Inc. (CDG.F)

8.42 0.00 (0.00%) At close: 03:32PM CEST

Acorda Therapeutics, Inc.

2 Blue Hill Plaza
3rd Floor
Pearl River, NY 10965
United States
914 347 4300
https://www.acorda.com

Sector(s): 
Industry: 
Full-time employees: 102

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ron Cohen M.D.	Founder, CEO, President & Director	832.47k	N/A	1956
Mr. Michael A. Gesser M.B.A.	CFO & Treasurer	567.3k	N/A	1963
Mr. Neil S. Belloff Esq.	General Counsel & Corporate Secretary	571.68k	N/A	1960
Ms. Denise J. Duca	Executive Vice President of Human Resources	N/A	N/A	N/A
Mr. Kerry M. Clem	Chief Commercial Officer	549.37k	N/A	1970
Sofia Ali	Senior VP of Operations & Strategic Planning	N/A	N/A	N/A
Susan Way	Senior VP of Drug Development & Regulatory Affairs	N/A	N/A	N/A
Dr. Wise Young M.D., Ph.D.	Special Scientific Advisor	9.28k	N/A	1950

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Corporate governance

Acorda Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.